Claims
- 1. A compound of the formula I,
- 2. A compound according to claim 1 wherein the ring A is an aromatic 6-membered ring containing 1 or 2 nitrogen atoms as ring heteroatoms.
- 3. A compound according to claim 1 wherein the ring A is an aromatic 5-membered ring containing a sulfur atom as ring heteroatom or a sulfur atom and a nitrogen atom as ring heteroatoms.
- 4. A compound according to claim 1 wherein n is 1.
- 5. A compound according to claim 1 wherein n is 3.
- 6. A compound according to claim 1, wherein R1 and R4 are independently from one another selected from the group consisting of H, C1-C4-alkyl and halogen and the residues R2 and R3 are independently from one another selected from the group consisting of H, C1-C4-alkyl and halogen.
- 7. A pharmaceutical preparation, comprising an pharmaceutically effective amount of a compound according to claim 1 and a pharmaceutically acceptable carrier.
- 8. A method for the stimulation of the expression of endothelial NO synthase, in a patient in need thereof, comprising administering to such patient a pharmaceutically effective amount of a compound of the formula I,
- 9. A method for the treatment of cardiovascular disease, stable or unstable angina pectoris, coronary heart disease, Prinzmetal angina, acute coronary syndrome, heart failure, myocardial infarction, stroke, thrombosis, peripheral artery occlusive disease, endothelial dysfunction, atherosclerosis, restenosis, endothel damage after PTCA, hypertension, essential hypertension, pulmonary hypertension, secondary hypertension, renovascular hypertension, chronic glomerulonephritis, erectile dysfunction, ventricular arrhythmia, diabetes, diabetes complications, nephropathy, retinopathy, angiogenesis, asthma bronchiale, chronic renal failure, cirrhosis of the liver, osteoporosis, restricted memory performance or a restricted ability to learn, or for the lowering of cardiovascular risk of postmenopausal women or of women taking contraceptives, in a patient in need thereof, comprising administering to such patient a pharmaceutically effective amount of a compound of the formula I
Priority Claims (1)
Number |
Date |
Country |
Kind |
02017586.5 |
Aug 2002 |
EP |
|
Parent Case Info
[0001] This application is entitled to the benefit of earlier filed U.S. Provisional Application No. 60/432,441, filed Dec. 11, 2002. The content of U.S. Provisional Application 60/432,441 is incorporated herein by reference.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60432441 |
Dec 2002 |
US |